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http://dx.doi.org/10.1016/j.cell.2016.09.037SUMMARY
Long-range interactions between regulatory ele-
ments and gene promoters play key roles in tran-
scriptional regulation. The vast majority of interac-
tions are uncharted, constituting a major missing
link in understanding genome control. Here, we use
promoter capture Hi-C to identify interacting regions
of 31,253 promoters in 17 human primary hematopoi-
etic cell types. We show that promoter interactions
are highly cell type specific and enriched for links be-
tween active promoters and epigenetically marked
enhancers. Promoter interactomes reflect lineage re-
lationships of the hematopoietic tree, consistent with
dynamic remodeling of nuclear architecture during
differentiation. Interacting regions are enriched in ge-
netic variants linked with altered expression of genes
they contact, highlighting their functional role. We
exploit this rich resource to connect non-coding dis-
ease variants to putative target promoters, priori-
tizing thousands of disease-candidate genes and
implicating disease pathways. Our results demon-
strate the power of primary cell promoter interac-
tomes to reveal insights into genomic regulatory
mechanisms underlying common diseases.Cell 167, 1369–1384, Novem
This is an open access article undINTRODUCTION
Genomic regulatory elements such as transcriptional en-
hancers determine spatiotemporal patterns of gene expres-
sion. It has been estimated that up to 1 million enhancer
elements with gene regulatory potential are present in
mammalian genomes (ENCODE Project Consortium, 2012).
Although a number of well-characterized enhancers map close
to their target genes, assignment based on linear proximity is
error prone, as many enhancers map large distances away
from their targets, bypassing the nearest gene (Mifsud et al.,
2015; Sanyal et al., 2012; Schoenfelder et al., 2015). Long-
range gene regulation by enhancers in vivo involves close
spatial proximity between distal enhancers and their target
gene promoters in the three-dimensional nuclear space (Carter
et al., 2002), most likely involving a direct interaction (Deng
et al., 2014), while the intervening sequences are looped
out. Thus, a comprehensive catalog of promoter-interacting
regions (PIRs) is a requisite to fully understand genome tran-
scriptional control.
Thousands of disease- and trait-associated genetic variants
have been identified by genome-wide association studies
(GWAS). The vast majority of these variants are located in non-
coding regions of the genome, often at considerable genomic
distances from annotated genes, making assessment of their
potential function in disease etiology problematic. However,
GWAS variants are enriched in close proximity to DNase Iber 17, 2016 ª 2016 The Authors. Published by Elsevier Inc. 1369
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Summary of PCHi-C Datasets Generated in This Study
Cell Type Acronym
Biological
Replicates Unique Captured Read Pairsa
Detected Promoter
Interactionsb
Megakaryocytes MK 4 653,848,788 150,779
Erythroblasts Ery 3 588,786,672 151,215
Neutrophils Neu 3 736,055,569 142,435
Monocytes Mon 3 572,357,387 165,947
Macrophages M0 M40 3 668,675,248 180,190
Macrophages M1 M41 3 497,683,496 171,031
Macrophages M2 M42 3 523,561,551 186,172
Endothelial precursors EndP 3 420,536,621 145,888
Naive B cells nB 3 629,928,642 189,720
Total B cells tB 3 702,533,922 213,539
Fetal thymus FetT 3 776,491,344 166,743
Naive CD4+ T cells nCD4 4 844,697,853 210,074
Total CD4+ T cells tCD4 3 836,974,777 199,525
Non-activated total CD4+ T cells naCD4 3 721,030,702 211,720
Activated total CD4+ T cells aCD4 3 749,720,649 213,235
Naive CD8+ T cells nCD8 3 747,834,572 216,232
Total CD8+ T cells tCD8 3 628,771,947 204,382
Total 11,299,489,740 698,187c
aTotal numbers of valid read pairs across all biological replicates are listed. See Table S1 for replicate-level statistics.
bInteractions with CHiCAGO scores >5. This excludes 9,396 interactions involving 484 captured non-promoter fragments that are not considered
further in the study.
cUnique interactions detected in at least one cell type.hypersensitive sites, potentially disrupting transcription factor
binding sites, suggesting that they may contribute to disease
by altering the function of distal regulatory elements in gene con-
trol (Maurano et al., 2012). Therefore, promoter interactions may
link disease-associated variants to their putative target genes
(Mifsud et al., 2015).
Recent advances in chromosome conformation capture
technologies such as Hi-C have increased the potential to un-
derstand long-range gene control. However, the enormous
combinatorial complexity of DNA fragment pairs in Hi-C libraries
impedes high-resolution detection of specific regulatory inter-
actions between individual genetic elements in a robust fashion.
Using sequence capture to enrich for Hi-C interactions that
involve specific regions of interest is a versatile approach to
overcome the limitations imposed by library complexity (Dryden
et al., 2014; Sahle´n et al., 2015; Schoenfelder et al., 2015).
We recently developed promoter capture Hi-C (PCHi-C), in
which sequence capture is used to pull down fragments con-
taining nearly all annotated promoters and their interacting
regions from Hi-C libraries, resulting in strong enrichment
for promoter interactions compared with Hi-C (Schoenfelder
et al., 2015).
Here, we apply PCHi-C in primary cells to generate a
comprehensive catalog of the interactomes of 31,253 annotated
promoters in 17 human primary blood cell types. Devising a
statistical methodology to link GWAS SNPs to their putative
target genes based on PCHi-C interaction data, we prioritize
thousands of new candidate genes potentially implicating a
number of gene pathways in susceptibility to common diseases.1370 Cell 167, 1369–1384, November 17, 2016RESULTS
Promoter Capture Hi-C
We performed PCHi-C experiments in 17 human primary blood
cell types (three or more biological replicates per cell type).
The Hi-C step was performed using in-nucleus ligation (Nagano
et al., 2015), and 22,076 fragments containing 31,253 annotated
promoters were captured to enrich the Hi-C material for pro-
moter interactions. Sequencing of the PCHi-C samples pro-
duced over 11 billion unique, valid read pairs involving promoters
(Tables 1 and S1). Comparison with Hi-C revealed a 15- to 17-
fold enrichment for promoter interactions, consistent with previ-
ous PCHi-C studies (Schoenfelder et al., 2015), equivalent in this
case to the promoter interaction detection power of over 165
billion conventional Hi-C read pairs. We used the CHiCAGO
pipeline (Cairns et al., 2016) to assign confidence scores to inter-
actions between the captured promoter fragments and PIRs
(Figures 1A–1C), detecting on average 175,000 high-confi-
dence interactions per cell type (CHiCAGO scoreR 5; Figure 1D;
Tables 1 and S1; Data S1), with a median of four interactions per
promoter fragment per cell type. More than half (55%) of PIRs
interacted with a single promoter fragment, while fewer than
10% PIRs had four or more promoter interactions per cell
type. We found abundant examples of tissue-specific and tis-
sue-invariant interactions (Figure 1C). In total, 698,187 high-con-
fidence unique promoter interactions were detected across all
cell types, of which 9.6% were promoter-to-promoter interac-
tions and 90.4% promoter-to-PIR, with a median linear distance
between promoters and their interacting regions of 331 Kb.
698,187 unique interactions across cell types 
~175,000 interactions per cell type
Physical interactions of
 31,253 annotated promoters
CHiCAGO
PCHi-C
17 primary
blood cell types
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Approximately 10%of promoter interactions were between frag-
ments greater than 1 Mb apart and 5,103 mapped across chro-
mosomes (‘‘trans-interactions’’). A total of 230,525 unique PIRs
were detected, linked to 20,676 captured fragments containing
29,992 annotated promoters (Figure 1D).
We also sequenced 16 pre-capture Hi-C libraries from eight
cell types (Table S1) and identified topologically associated
domains (TADs) using the directionality index score (Dixon
et al., 2012) (Figure 1B). We found that about a third of PCHi-
C-identified interactions crossed TAD boundaries, which is
significantly below that expected at random in all eight cell types
(Figures 1E and S1A), consistent with previous results (Schoen-
felder et al., 2015). The frequency of TAD boundary-crossing
interactions was broadly similar for both promoters adjacent
to the boundaries and those located in the centers of TADs
(on average, 32% and 28.5% respectively).
We chose approximately 1,000 identified PIRs for validation,
using them as capture baits in a reciprocal capture system that
we applied to eight Hi-C libraries from four cell types (Figure S2A;
Table S1; and Data S1). The CHiCAGO interaction scores of
PCHi-C and reciprocal capture Hi-C aligned well (Figure S2
and Quantification and Statistical Analysis), thus validating our
approach.
Promoter Interactomes Are Lineage and Cell Type
Specific
Principal component analysis (PCA) of CHiCAGO interaction
scores across all biological replicates of the 17 cell types re-
vealed close clustering of the replicates and separation of the
individual cell types (Figure 2A). This demonstrates signal
reproducibility across replicates and suggests strong cell-type
specificity of the interactomes. We noted that neutrophils
showed a distinct PCA profile, potentially reflecting their unusual
segmented nuclearmorphology. Hierarchical clustering of the 17
cell types based on their CHiCAGO interaction scores demon-
strated that patterns of promoter interactions across the cell
types segregated in a manner generally consistent with the he-
matopoietic tree (Figure 2B, top). We further confirmed the
cell-type specificity and lineage relationships of the interactomes
globally using conventional Hi-C at the level of large-scale A/B
nuclear compartments (Figures S1B–S1D).Figure 1. Promoter Capture Hi-C across 17 Human Primary Blood Cell
(A) Schematic representation of the project.
(B) Interaction landscape of INPP4B gene promoter along a 5-Mb region in naive
mapping, on one end, to the captured HindIII fragment containing INPP4B gene
x axis coordinate; the y axis shows read counts per di-tag. Red dots denote hig
promoter are shown as red arcs. Gray lines denote expected counts per di-tag ac
bound of the 95% confidence interval. Genes whose promoters were found to phy
interact with specific DNase hypersensitivity sites (DHSs, middle panel) defined in
within the same topologically associated domain (TADs, black line, as defined ac
TAD boundaries. A conventional Hi-C profile for the same locus in nCD4 cells is
(C) Interaction landscape of the INPP4B, RHAG, ZEB2-AS, and ALAD promoters
as in (B), with high-confidence PIRs shown in red (CHiCAGO scoreR5) and sub
(D) The numbers of unique interactions (left) and PIRs (right) detected for a given
random orderings of cell types; gray ribbons show SDs.
(E) Proportions of interactions crossing TAD boundaries per cell type; observed
show ±SD across 1000 permutations (see Quantification and Statistical Analysis
See also Figures S1 and S2, Table S1, and Data S1.
1372 Cell 167, 1369–1384, November 17, 2016We then used Autoclass Bayesian clustering (Cheeseman
et al., 1988) to partition promoter interactions based on their
CHiCAGO scores across cell types, which produced 34 distinct
interaction clusters (Figure 2B, heatmap). Just under half (47.4%)
of interactions mapped to predominantly lymphoid-specific
clusters (1–15, 25, 26) (Figures 2B and 2C). Examples of genes
whose promoter interactions predominantly map to this set of
clusters include T cell receptor components (CD247, CD3D,
and CD3G), as well as IKZF3 coding for the AIOLOS protein
that has a key role in lymphoid development. 38.9% of the inter-
actions mapped to generally myeloid-specific clusters (16–18,
27–34). Promoters with predominant interactions in this set of
clusters include, for example, DIP2C (Disco-Interacting Protein
2 Homolog C) that shows high expression in acute myeloid
leukemia. Clusters 19–24, containing 13.6% of interactions,
showed strong signal in both lineages.
We found that just over 60% of captured promoter fragments
hadat least one interactiondetected inbothmyeloidand lymphoid
lineages, however nearly all of them (>99%) also engaged in
additional lineage- or cell-type-specific interactions (Figure S3A).
On the whole, interactions sharing the same promoter fragment
tended to have more similar cell-type specificities than expected
at random (Figure S3B). This suggests a complex and potentially
cooperative effect of cell-type-specific and invariant interactions
in setting up genome organization and expression.
Collectively, the cell-type specificity and lineage relatedness
of promoter interactomes suggests that higher-order genome
structure undergoes widespread and coordinated remodeling
during lineage specification, dynamically reshaping transcrip-
tional decisions.
Promoter-Interacting Regions Are Enriched for
Regulatory Chromatin Features
PIRs were significantly enriched for regions of accessible
chromatin (Figure S3C), with 56% containing accessible re-
gions detected by assay for transposase-accessible chromatin
sequencing (ATAC-seq) in at least one blood cell type (Corces
et al., 2016). This points to the regulatory potential of many
PIRs. To further investigate this, we studied the chromatin prop-
erties of PIRs using data from the BLUEPRINT project from
the nine blood cell types, for which sufficient information wasTypes
CD4+ (nCD4) cells (PCHi-C, top panel). Each dot denotes a sequenced di-tag
promoter, and on the other end, to another HindIII fragment located as per the
h-confidence PIRs (CHiCAGO score R5), and their interactions with INPP4B
cording to the CHiCAGO background model, and dashed lines show the upper
sically interact with INPP4B promoter are labeled in bold. Promoters selectively
the same cell type from the ENCODE project. Some of these interactions occur
cording to the standardized directionality index score, sDI), while others span
shown in the bottom panel.
in naive CD4+ cells (nCD4), erythroblasts (Ery), and monocytes (Mon). Dot plots
-threshold PIRs (3 < CHiCAGO score < 5) shown in blue.
number of analyzed cell types. Lines and dots show the mean values over 100
and expected frequencies of TAD boundary-crossing interactions. Error bars
).
A
PC
1
−1500 −1000 −500 0 500
−1
00
0
−5
00
0
50
0
10
00
PC2
o
oo
o
o
o
ooo
o
oo
oo
o
o oo
o
o
o
ooo
o
o
o o
o
o
o
oo
o
o
o
o
o
o
o o
o
o
o
o
oo
o
o
o
o
Neu Mon
Mon
Mon
Ery
Ery
Ery
Neu
Neu
Mφ0
Mφ0
Mφ0
Mφ1
Mφ1
Mφ1
EndP
EndP
EndP
Mφ2
Mφ2
Mφ2
MK
MK
MK MK
FetT
FetT
FetT
tB
tB tB
nB nB
nB
−500 0 500
−4
00
0
40
0
80
0
PC2
PC
1
nCD4
nCD4
nCD4
nCD4
nCD8nCD8 nCD8
aCD4
aCD4
aCD4
tCD4
tCD4 tCD4
naCD4
naCD4
naCD4
tCD8tCD8tCD8
O
O
O
O
O
O
O
O
O O
O
O O
O
O
O
OOO
C
B
nC
D
4
nC
D
8
Fe
tT
nB M
on
N
eu
M
φ2
M
φ0
M
φ1
E
ry
M
K
E
nd
P
tC
D
4
aC
D
4
na
C
D
4
tC
D
8
tB
−3
−1
1
3
MyeloidLymphoid
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
1
2
3
4
5
6
7
8
10-14
15
16
17-18
19-20
21
22-24
25-26
27-30
31
32
33
34
nC
D
4
nC
D
8
Fe
tT
nB M
on
N
eu
M
φ2
M
φ0
M
φ1
E
ry
M
K
E
nd
P
tC
D
4
aC
D
4
na
C
D
4
tC
D
8
tB
30
0
40
0
60
0
MyeloidLymphoid
2
0
6
4
>8
M
on
N
eu
M
φ2
M
φ0
M
φ1
E
ry
M
K
E
nd
P
nC
D
4
nC
D
8
Fe
tT
nB tC
D
4
aC
D
4
na
C
D
4
tC
D
8
tB
C
lu
st
er
 ID
H
ei
g
h
t
50
0
Cluster 
specificity
score
CHiCAGO
interaction
score
C
lu
st
er
 ID
Figure 2. Promoter Interactions Reflect the Lineage Relationships of the Hematopoietic Tree
(A) Principal Component Analysis (PCA) of the CHiCAGO interaction scores for each individual biological replicate (nB, naive B cells; tB, total B cells; FetT, fetal
thymus; aCD4, activated CD4+ T cells; naCD4, non-activated CD4+ T cells; tCD4, total CD4+ T cells; nCD8, naive CD8+ T cells; nCD4, naive CD4+ T cells; tCD8,
total CD8+ T cells; Mon, monocytes; Neu, neutrophils; M40–2, Macrophages M0, M1, M2; EndP, endothelial precursors; MK, megakaryocytes; Ery, erythro-
blasts). The inset shows the results of a separately performed PCA for CD4+ and CD8+ T cells only.
(B) Top (dendrogram): hierarchical clustering of the cell types according to their promoter interaction profiles. Bottom (heatmap): Autoclass Bayesian clustering of
interactions according to their cell-type specificity. Cluster IDs are shown on the right. Cluster 9 containing 108,066 interactions is not shown for clarity.
(C) Cell-type specificity of interaction clusters. The heatmap shows cluster specificity scores in each cell type (see Quantification and Statistical Analysis for
details). Cell types and clusters are arranged as in (B).
See also Figures S3A and S3B.available (Figure 3). We found PIRs to be significantly enriched
for histone marks associated with active enhancers, such as
H3K27ac and H3K4me1, in comparison with distance-matched
random controls (Figures 3A and 3B). We also found enrichmentfor H3K4me3 and H3K36me3 at PIRs, which are marks associ-
ated with active promoters and transcribed regions, respec-
tively, consistent with non-coding transcription of regulatory
regions (Natoli and Andrau, 2012).Cell 167, 1369–1384, November 17, 2016 1373
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We then focused on regions annotated as promoters and en-
hancers in the Ensembl Regulatory Build (Zerbino et al., 2015),
defining their activity on the basis of ChromHMM (Ernst and
Kellis, 2012) segmentations of the BLUEPRINT histone ChIP
data. We asked whether the cell-type-specific activity state
of enhancers depended on their connectivity to promoters, or
alternatively, whether enhancer-promoter interactions tended
to be primed irrespective of enhancer activity (Ghavi-Helm
et al., 2014). Consistent with previous findings in the b-globin
locus (Tolhuis et al., 2002), Figures 3C and S3D show that inter-
actions between the Locus Control Region (LCR) enhancers and
theHBB andHBG genes occur in erythroblasts, in which they are
active, but not in monocytes or CD4+ T cells. We observed this
activity-state-dependent connectivity of enhancers with pro-
moters globally (Figure 3D), and formally confirmed it using over-
dispersion-adjusted statistical tests (Figures 3E and 3F). These
results demonstrate that the dynamic nature of enhancer-
promoter interactions is preferentially coupled with the cell-
type-specific activity of the regulatory elements they connect.
Enhancer Activity Associates with Lineage-Specific
Gene Expression
To gain insight into the role of promoter contacts in regulating
lineage-specific gene expression, we integrated information
on chromatin states at promoters and enhancers with global
gene expression profiles in the same cells available from the
BLUEPRINT consortium. Comparing gene expression across
cell types, we observed that promoter interactions with active
enhancers generally had an additive effect on cell-type-specific
expression levels (p < 23 1016; Figure 4A). Notably, a weak, but
also significant additive effect was observed when all PIRs, irre-
spectively of their annotation, were considered for the analysis
(p < 23 1016; Figure S4A), with the fraction of active enhancers
among them providing an independent predictor (p < 23 1016;
data not shown). These results confirm that active enhancers,
and potentially other elements devoid of canonical enhancer
features, quantitatively contribute to gene expression.
We then sought to partition genes based on the cell-type spec-
ificity of their interactions with active enhancers. For each gene,
we used CHiCAGO interaction scores and enhancer activity
states to calculate a ‘‘gene specificity score’’ for each cell type
(see Quantification and Statistical Analysis). Applying k-meansFigure 3. Promoters Preferentially Connect to Active Enhancers
(A) PIR enrichment for histone marks compared with distance-matched random
(B) Significance of PIR enrichment for histone marks from (A), expressed in term
(C) Promoter interactions and chromatin features in the b-globin locus. PCHi-C
Ensembl Regulatory Build, colored by feature, and chromatin activities based o
image is based on a screenshot produced with Ensembl v83 using GRCh37 assem
(LCR) is highlighted (blue box).
(D) Enrichment of PIRs for active distal enhancers (shown per biological replicate
(E) Enrichment of promoter-enhancer interactions for links between active promot
of promoter and enhancer activity connected by an interaction are color coded
promoter and enhancer states at either ends of interactions. The non-active ca
defined with chromHMM.
(F) Interactions between an active promoter and an enhancer are preferentially fou
each combination of enhancer activity and the presence or absence of interact
independence of the enhancer state and the presence of interaction. The non-ac
See also Figure S3C.clustering to the resulting gene specificity scores, we obtained
the 12clusters shown inFigure4B.This revealedclustersof genes
with predominant enhancer specificity in one or multiple related
cell types, andaclusterwithnopredominant specificity (cluster 9).
We compared the gene specificity scores based on interac-
tions with active enhancers with analogous scores that capture
cell-type specificity of the respective genes’ expression. As
shown in Figures 4C and S4B, genes mapping to a cell-type-
specific cluster based on their interactions with active enhancers
were, on average, preferentially expressed in the same cell type.
The link between cell-type specificity of active enhancer inter-
actions and gene expression was the most apparent when
focusing on genes expressed with the highest cell-type speci-
ficity (Figures 4D, 4E, and S4C). For example, 46% of the top
100 lymphoid-specifically expressed genes mapped to cluster
eight characterized by lymphoid-specific active enhancer inter-
actions, while an additional 37% mapped to clusters with active
enhancers specific to both nCD4 cells and other cell types
(Figure 4D). Taken together, these results support a direct func-
tional role of the identified enhancer-promoter interactions in
transcriptional control.
Expression Quantitative Trait Loci Provide Evidence for
PIR Regulatory Function
Natural genetic variation has been described as an ‘‘in vivomuta-
genesis screen’’ (Heinz et al., 2013). Here, we used data on
sequence variants associated with altered expression of specific
genes (expression quantitative trait loci, eQTLs) in primary
monocytes and B cells (Fairfax et al., 2012) to demonstrate PIR
function. Integrating eQTL information with PCHi-C results, and
considering at most one ‘‘lead’’ eQTL per gene, we found 899
lead eQTLs in monocyte PIRs and 577 in B cell PIRs that physi-
cally contact the promoters of the genes they regulate (false
discovery rate [FDR] <10%; Table S2). To confirm the specificity
of eQTL localization to PIRs, we randomized PIR locations ac-
counting for interaction distance and compared the proportions
of variants that are eQTLs at PIRs and at these random regions.
We found that PIRs are selectively enriched for eQTLs regulating
the same gene that the PIR is connected to, across a broad
range of linear distances from their target promoters (Figures
5A and 5B). We found a similar enrichment when considering
at most one eQTL variant per gene (Figures S5A and S5B). Theseregions. Error bars show SD across 100 draws of random regions.
s of Z scores.
data from three cell types, showing regulatory element annotations from the
n ChromHMM segmentations of BLUEPRINT histone modification data. The
bly and GENCODE v19 gene annotations. The b-globin Locus Control Region
).
ers and active enhancers. The observed to expected ratios of each combination
. The p value is for the overdispersion-adjusted c2 test of independence of
tegory includes the ‘‘poised,’’ ‘‘Polycomb-repressed,’’ and ‘‘inactive’’ states
nd in cell types, in which the enhancer is active. Observed to expected ratios for
ion are color coded. The p value is for the overdispersion-adjusted c2 test of
tive category is as in (E).
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results demonstrate that variants in physical contact with gene
promoters are significantly more likely to have regulatory effects
on the genes they contact compared with other variants
matched by distance. Taken together, these findings provide
robust functional support for over 1,000 promoter interactions
in monocytes and in B cells.
The identification of eQTLs is affected by the power of the
eQTL study. Therefore, we additionally considered eQTLs from
a larger meta-analysis in whole blood (Westra et al., 2013).
We found 1,214 lead cis-eQTLs in whole blood are located in
PIRs that physically contact the respective eQTL target gene
promoters in at least one analyzed cell type (Table S2), which
significantly exceeded random expectation (p < 1e-3; Fig-
ure S5C). In total, PIRs detected in our study overlapped
25.7% of all lead cis-eQTLs in whole blood for the respective
PIR-connected genes. Collectively, these results provide abun-
dant evidence of PIR function.
Examples of eQTLs at PIRs included those with effects
on more than one gene. For instance, eQTL SNP rs71636780
localizes to a PIR of two genes, ARID1A and ZDHHC18 in
monocytes (located 50 and 100 kb away, respectively), with
its variants showing opposite effects on expression of these
genes (Figure 5C). In contrast, eQTL SNP rs117561058 within
a PIR of NDUFAF4 and ZBTB2 shows consistent effects on
the expression of both genes. Strikingly, this PIR is located
10 and 60 Mb from NDUFAF4 and ZBTB2, respectively (Fig-
ure 5D). Further examples of long-range PIRs harboring eQTLs
are shown in Figures S5D and S5E.
Notably, we found 194 monocyte eQTLs, 118 B cell eQTLs,
and 310 whole-blood eQTLs at PIRs containing promoter re-
gions of other genes, suggesting that promoter-promoter inter-
actions may have regulatory effects. This is consistent with
previous findings for the INS and SYT8 genes (Xu et al., 2011)
and emerging genome-wide data (I. Jung and B. Ren, personal
communication).
Taken together, expression quantitative trait loci provide func-
tional and statistically supported evidence for a regulatory role of
the PCHi-C-identified promoter interactions and demonstrate
their potential to link non-coding regulatory variants with target
genes.
Promoter Interactions Prioritize Putative Target Genes
of Disease-Associated SNPs
We integrated PCHi-C data with summary statistics from 31
GWAS, including eight autoimmune diseases, eight blood cell
traits, and nine metabolic and six other traits (Table S3). To
assess cell-type-specific enrichment of GWAS signals at PIRs,Figure 4. Active Enhancers at PIRs Associate with Lineage-Specific G
(A) Plot of log2-gene expression as a function of the number of interacting active
regression. Asterisks above and below the boxplots reflect the fact that some ou
(B) Heatmap of ‘‘gene specificity scores’’ for 7,004 protein-coding genes uniquely
enhancers in each of eight cell types (columns). Genes are partitioned using k-m
(C) Mean gene specificity score (based on interactions with active enhancers) fo
scores based on expression data for nCD4, MK, Ery and Neu cells. Error bars in
(D) Subset of the heatmap in (B), showing interaction-based gene specificity score
(E) Enrichment of the 12 clusters shown in (B) for the 100 genes expressed with h
Analysis for details).
See also Figure S4.we devised blockshifter, a method that takes into account corre-
lation structure in both GWAS and PIR datasets (Figure S6A). We
found that variants associated with autoimmune disease are en-
riched at PIRs in lymphoid compared tomyeloid cells (Figure 6A).
In contrast, SNPs associated with platelet- and red-blood-cell-
specific traits were predominantly enriched at PIRs in myeloid
lineages (Figure 6A). Finally, SNPs associated with traits gener-
ally unrelated to hematopoietic cells, such as blood pressure
(systolic, BP S, and diastolic, BP D) and bone mineral density
(in femoral neck, femoral neck mineral density [FNMD], and
lumbar spine, lumbar spine mineral density [LSMD]) were
not selectively enriched at PIRs in any analyzed cell types
(Figure 6B). Collectively, these results confirm the selective
enrichment of GWAS variants at PIRs in putative disease- and
trait-relevant cell types.
We next developed a Bayesian prioritization strategy termed
COGS (Capture Hi-C Omnibus Gene Score) for using promoter
interaction data to rank putative disease-associated genes
and tissues across the 31 GWAS traits. This algorithm integrates
statistical fine mapping of GWAS signals across SNPs mapping
to gene coding regions, promoters, and PIRs to provide a
single measure of support for each gene. Figure 6C shows
an example of the COGS algorithm at work in the 1p13.1
rheumatoid arthritis (RA) susceptibility region, prioritizing RP4-
753F5.1, CD101, TTF2, and TRIM45 as RA candidate genes
(Figure 6C, bottom panel). A possible role for CD101 in RA was
previously reported (Jovanovic et al., 2011). Future work may
establish whether the other genes prioritized on the basis of
the same GWAS SNP-harboring PIR (Figure 6C, white bar) also
contribute toward disease, since a single element may regulate
multiple genes, as evidenced by eQTL examples in Figures 5C
and 5D and previous studies (Hanscombe et al., 1991; Mohrs
et al., 2001).
Using the COGS algorithm genome-wide for 31 diseases and
blood cell traits, we prioritized a total of 2,604 candidate genes
(with a median of 122 genes per trait at gene-level score >0.5;
Table S3). The prioritized genes exhibited both expected and un-
expected enrichments for specific pathways in the Reactome
Pathway Database (Fabregat et al., 2016). In particular, and as
expected, genes prioritized for autoimmune diseases were en-
riched in inflammation and immune-response-related pathways,
such as interleukin and T cell receptor signaling, whereas genes
prioritized for platelet traits were preferentially associated with
platelet production and hemostasis (Figure 6D). Less obvious
pathway associations included free oxygen species metabolism
in celiac disease (Yang et al., 2015), and post-translational and
epigenetic modifications of proteins and nucleic acids in theene Expression
enhancers in cell types, where the promoter is active. Trendline shows linear
tlying observations have been cropped.
mapping to a captured fragment (rows), based on their interactions with active
eans clustering.
r each of the clusters in (B) plotted against analogous mean gene specificity
dicate ±SD. Plots for Mon and M41–3 are shown in Figure S4B.
s for the top 100 nCD4-specifically expressed genes, together with cluster IDs.
ighest specificity in each analyzed cell type (see Quantification and Statistical
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Figure 5. Promoter-Interacting Regions Are Enriched for Interacting Gene eQTLs
(A and B) The proportion of SNPs that are eQTLs for the PIR-connected gene compared with the equivalent proportion at matched random regions (‘‘randomized
PIRs’’) in monocytes (A) and total B cells (B). Asterisks represent the significance of enrichment at observed versus randomized PIRs (permutation test *p < 0.05;
**p < 0.01; ***p < 0.001).
(C and D) Examples of a single common eQTL SNP identified for two genes (ARID1A and ZDHHC18, C; NDUFAF4 and ZBTB2, D) with either the opposite (C) or
the same (D) directionality of effect. SNPs have been tested within PIRs plus additional 500-bp windows on both sides of them. The Manhattan plots (bottom
panel) depict the eQTL signals for both genes. The gray dashed line represents the significance threshold.
See also Figure S5 and Table S2.red blood cell traits (Figure 6D), inviting further in-depth vali-
dation by specialist communities. The COGS prioritization strat-
egy produced distinct results from a ‘‘brute-force’’ approach
based on promoter colocalization with disease susceptibility
regions (DSRs) within the same TADs, which yielded con-
siderably more candidates per disease (on average, 5-fold1378 Cell 167, 1369–1384, November 17, 2016more), and did not capture all those prioritized with COGS
(Figure S6B).
We further focused on a subset of 421 highest-scoring genes
prioritized for at least one autoimmune disease. Taking into ac-
count known and predicted protein-protein interactions and
pathway co-localization of their products, we constructed a
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consolidated ‘‘autoimmune disease network’’ (Figure 6E). The
highly connected core of this network (Figure 6E, inset) in-
cludes cytokine genes such as IL19 and IL24, signaling and
transcription factors controlling proliferation, inflammation and
lineage identity (such as MYC, JAK1/2, ETS1/2, CDKN1B,
NFKB1, FOXO1, and IKZF2/3). According to ImmunoBase
(http://www.immunobase.org), the majority (76%) of the genes
in the core autoimmune disease network were not previously
implicated as causal candidates for autoimmune diseases, and
65% fall outside of known DSRs (Table S3).
We compared COGS-prioritized genes for Crohn’s disease
(CD) and ulcerative colitis (UC) with genes found to be differen-
tially expressed in at least one of five sorted immune cell
populations from inflammatory bowel disease (IBD) patients
(Peters et al., 2016). A total of 33/182 (18.1%) and 49/278
(17.6%) genes prioritized by COGS for CD and UC, respectively,
were differentially expressed in IBD patients. This corresponds
to a significant enrichment of COGS-prioritized genes for differ-
ential expression in disease (Fisher’s exact test p = 0.007 and
p = 0.016, respectively; Figure S6C). Notably, significant enrich-
ment was not observed for genes prioritized on the basis of
shared TADs (Figure S6C). The majority of the COGS-prioritized
differentially expressed genes (20/33 and 44/49, respectively)
were not previously implicated in these diseases based on
GWAS results. This provides further functional evidence for our
prioritization strategy.
Finally, we used the RA and systemic lupus erythematosus
(SLE) GWAS datasets (Bentham et al., 2015; Okada et al.,
2012), for which imputed results are publicly available, to ask
whether the GWAS signals that drove candidate gene prioritiza-
tion are supported by eQTLs in the respective LD blocks.
Genome-wide, this analysis revealed that out of 456 genes prior-
itized for these two diseases, 136 had eQTLs, of which four
genes (BLK, RASGRP1, SUOX, and GIN1) showed evidence
for possible co-localization of GWAS signals and eQTLs in RA
and two genes (BLK and SLC15A4) in SLE (see Figure S6
for examples). In addition, the genes prioritized for RA includedFigure 6. Promoter Interactions Link GWAS SNPs with Putative Target
(A) Enrichment of GWAS summary statistics at PIRs by tissue type. Axes reflect b
versus myeloid, then additionally within the myeloid lineage. Traits are labeled an
BP_S, systolic blood pressure; CD, Crohn’s disease; CEL, celiac disease; FNBMD
sensitivity BMI-adjusted; HB, hemoglobin; HDL, high-density lipoprotein; HEIGH
low-density lipoprotein; LSBMD, lumbar spine bonemineral density; MCH,mean c
MCV, mean corpuscular volume; MS, multiple sclerosis; PBC, primary biliary cirr
rheumatoid arthritis; RBC, red blood cell count; SLE, systemic lupus erythrema
triglycerides; UC, ulcerative colitis).
(B)Blockshifter enrichment Z scores of GWAS summary statistics in PIRs by individ
the labeled tissue; green indicates enrichment in the endothelial cell control.
(C) Example of the COGS gene prioritization method in 1p13.1 RA susceptibility re
are transformed into posterior probabilities for variant being causal (middle), whic
LD, to compute gene scores. Arcs representing promoter-PIR interactions are co
(D) Bubble plot of traits with significant enrichment (p.adj < 0.05) in one or more
indicate the total number of genes analyzed for each trait (gene score >0.5), bubb
corresponds to decreasing adjusted p value for enrichment.
(E) The ‘‘core autoimmune disease network’’ containing the 421 highest-scoring g
on diseases for which theywere prioritized as candidates by the COGS algorithm.
interactions, predicted interactions and pathway associations obtained from Ge
gene names for the highest-connected central part of the network. See Quantific
See also Figure S6 and Table S3.
1380 Cell 167, 1369–1384, November 17, 20165/9 candidates (C8Orf13, BLK, TRAF1, FADS2, and SYNGR1)
that were identified in a recent study (Zhu et al., 2016) combining
whole-blood eQTL with RA GWAS data by Mendelian ran-
domization. The relatively large number of prioritized genes
without eQTL support is in agreement with previous reports of
limited overlap of disease variants with eQTLs (Guo et al.,
2015). This demonstrates complementary benefits of eQTL-
based and physical-interaction-based approaches for priori-
tizing candidate target genes of non-coding disease variants.
Taken together, our results reveal large numbers of newly
identified potential disease genes and pathways and demon-
strate the power of high-resolution 3D promoter interactomes
for large-scale interpretation of GWAS data.
DISCUSSION
Wehave presented a comprehensive analysis of promoter-asso-
ciated genome architecture in human primary hematopoietic
cells. We show that promoter interactomes are highly cell type
specific, enriched for links between active promoters and active
enhancers and reflect the lineage relationships of the hemato-
poietic tree. Collectively, these results suggest that three-dimen-
sional genome architecture undergoes stepwise remodeling
during lineage specification.
Theoretically, enhancer-promoter contacts can be either
‘‘instructive’’ (triggering transcriptional activation) or ‘‘permis-
sive’’ (poised for activation) (de Laat and Duboule, 2013). The
mechanistically verified model of instructive interactions are
loops in the b-globin locus (Deng et al., 2014). Our observations
in blood cells provide additional evidence for the ‘‘instructive’’
model. However, it is likely that both mechanisms are opera-
tional, particularly in early development. For example, permis-
sive interactions were previously detected for early mesodermal
enhancers in Drosophila (Ghavi-Helm et al., 2014), in mouse
embryonic stem cells (Schoenfelder et al., 2015), as well as for
tumor necrosis factor alpha (TNF-a) response genes in fibro-
blasts (Jin et al., 2013).Genes
lockshifter Z scores for two different tissue group comparisons, first lymphoid
d colored by category (BMI, body mass index; BP_D, diastolic blood pressure;
, Femoral neck bonemineral density; GLC, glucose sensitivity; GLC_B, glucose
T, height; INS, insulin sensitivity; INS_B, insulin sensitivity BMI-adjusted; LDL,
orpuscular hemoglobin; MCHC,mean corpuscular hemoglobin concentration;
hosis; PCV, packed cell volume; PLT, platelet count; PV, platelet volume; RA,
tosis; T1D, type 1 diabetes; T2D = type 2 diabetes; TC, total cholesterol; TG,
ual tissue type using endothelial cells as a control. Red indicates enrichment in
gion. GWAS summary p values for association with RA (Okada et al., 2012) (top)
h are then aggregated at all PIRs interacting with a given gene, accounting for
lor coded with genes.
pathways from the Reactome database (Fabregat et al., 2016). Top numbers
le size indicates the ratio of test genes to those in the pathway, and blue to red
enes prioritized for autoimmune disease. Genes (nodes) are color coded based
Edges between genes are drawn based on prior knowledge about their physical
neMania (Montojo et al., 2010) and are color coded accordingly. Inset shows
ation and Statistical Analysis.
High-resolution interaction information makes it possible to
connect genes to their enhancers. Using this approach, we
observe that enhancers show generally additive effects on the
expression of their target genes, which may explain why genes
are often able to buffer the effects of mutations at individual en-
hancers (Frankel et al., 2010;Waszak et al., 2015). This buffering,
in turn, may underlie the fact thatmany non-coding GWASSNPs,
while enriched at regulatory regions, are not detectable as
eQTLs, particularly under normal conditions (Guo et al., 2015).
Interestingly, we also observed additive effects, albeit weaker,
for PIRs that were not annotated as enhancers. This provides
additional support to recent findings that regions without
‘‘classic’’ enhancer or other gene regulatory signatures may
also be involved in activation of gene expression (Rajagopal
et al., 2016). However, we do not imply that all PIRs have gene
regulatory roles in the analyzed cell types. Some promoter inter-
actions may have structural or topological roles, whereas others
could be remnants of past developmental stages or priming for
future activation.
Using naturally occurring sequence variants that affect
expression of specific genes (eQTLs), we provide abundant
evidence for PIR function in gene expression control, demon-
strating the power of PCHi-C to link non-coding regulatory vari-
ants with their target genes. Recent studies by ourselves and
others have made a strong case for using 3D genome
information to interpret non-coding disease-associated variants
(Davison et al., 2012; Dryden et al., 2014; Martin et al., 2015;
Mifsud et al., 2015; Smemo et al., 2014; Stadhouders et al.,
2014). Here, we link thousands of GWAS SNPs to their putative
target genes and prioritize more than 2,500 potential disease-
associated genes, three-quarters of which were not previously
implicated. These candidates map to expected and novel gene
pathways. While further validation will be required to firmly
establish the links to specific diseases, our work establishes a
systematic approach to interpret non-coding genetic variation
and creates an unprecedented opportunity to unlock the seem-
ingly intractable promise created by current and future GWAS.STAR+METHODS
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Antibodies
CD41 BD cat#555466
CD42 IBGRL cat#9448
CD71 BD cat#551374
CD235 BD cat#555570
CD66b-FITC IBGRL cat#9453FL
CD16PE Miltenyi cat#130-091-245
CD14-FITC BD cat#345784
CCR7-FIT BD cat#5612271
CD25-PE Miltenyi cat#120-001-311
CD14-PEcy5.5 Invitrogen cat#MCHD1418
CD40-PEcy7 BD cat#561215
CD206-P BD cat#555954
CD36-FITC Southern Biotech cat#9605-02
CD36-FITC BD cat#555454
CD45-PEcy5.5 Invitrogen cat#MCHD4518
CD27 PE BD cat#555441
IgD-FITC BD cat#555778
CD19 APC BD cat#555415
CD4-FITC BD cat#555346
CD45ra PE BD cat#555489
CD3 BD cat#555332
CD8 BD cat#555367
CD62L BD cat#559772
CD45RA BD cat#555489
CD8-FITC BD cat#555366
CD3-brilliant violet 421 Biolegend cat#300434
CD4-BUV395 BD cat#563550
CD45RA-brilliant violet 785 Biolegend cat#304123
CD25-APC BD cat#555434 and cat#340907
CD127-PECy7 Biolegend cat#351320
CD62L-brilliant violet 605 BD cat#562719
Critical Commercial Assays
CD34 microbead kit Miltenyi cat#130-046-702
CD16 microbead kit Miltenyi cat#130-045-701
CD14 microbead kit Miltenyi cat#130-050-201
Monocyte negative selection isolation kit StemCell technologies cat#19059
EasySep human naive B cell enrichment kit StemCell technologies cat#19254
EasySep human B cell enrichment kit StemCell technologies cat#19054
EasySep custom kit for Naive CD4 StemCell technologies cat#19309
EasySep human CD4+ T cell enrichment kit StemCell technologies cat#19052
RosetteSep Human CD4+ T cell enrichment
cocktail
StemCell technologies cat#15022
Dynabeads Human T activator CD3/
CD28 beads
Thermofisher cat#111.31D
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EasySep Human Naive CD8+ T cell enrichment kit StemCell technologies cat#19158
EasySep Human CD8+ T cell enrichment kit StemCell technologies cat #19053
Quant-iT PicoGreen dsDNA Assay Kit Thermofisher cat#P7589
SureSelectXT Custom 3-5.9Mb library Agilent Technologies cat#5190-4831
SSEL TE Reagement Kit, ILM PE full adaptor Agilent Technologies cat#931108
SureSelectXT Custom 1Kb-499kb library Agilent Technologies cat#5190-4806
Deposited Data
Raw Promoter Capture Hi-C and reciprocal
capture Hi-C data
This study EGA: EGAS00001001911
Processed data generated in this study This study https://osf.io/u8tzp
BLUEPRINT raw gene expression data BLUEPRINT project EGA: EGAS00001000327
H3K4me3 CHIPseq in human CD20+ cells. ENCODE project https://www.encodeproject.org/experiments/
ENCSR000DQR/ENCFF001WXC
DNase-seq in human naive CD4+ cells ENCODE project https://www.encodeproject.org/experiments/
ENCSR000EML/
Histone modification ChIP data BLUEPRINT project
(GRCh37-based release)
ftp://ftp.ebi.ac.uk/pub/databases/blueprint/
data/homo_sapiens/GRCh37/
Ensembl regulatory build Zerbino et al., 2015 ftp://ftp.ebi.ac.uk/pub/contrib/pchic/hg19/
overview/RegBuild.bb
ATAC-seq data Corces et al., 2016 GEO: GSE74912
Monocyte and B cell eQTL data Fairfax et al., 2012 EGA: EGAS00000000109; ArrayExpress:
E-MTAB-2232
Whole blood eQTL data Westra et al., 2013 http://genenetwork.nl/bloodeqtlbrowser/2012-
12-21-CisAssociationsProbeLevelFDR0.5.zip
Blood trait GWAS summary data Gieger et al., 2011;
van der Harst et al., 2012
Obtained from authors
Autoimmune disease GWAS summary data Anderson et al., 2011;
Barrett et al., 2009; Bentham
et al., 2015; Cordell et al.,
2015; Dubois et al., 2010;
Franke et al., 2010; Sawcer
et al., 2011; Stahl et al., 2010
http://www.immunobase.org
Type 2 diabetes GWAS summary data Morris et al., 2012 http://diagram-consortium.org/downloads.html
Height GWAS summary data Wood et al., 2014 https://www.broadinstitute.org/collaboration/
giant/images/0/01/GIANT_HEIGHT_Wood_et_al_
2014_publicrelease_HapMapCeuFreq.txt.gz
Tryglycerides GWAS summary data Teslovich et al., 2010 http://csg.sph.umich.edu/abecasis/public/
lipids2010/TG2010.zip
High density lipoprotein GWAS summary data Teslovich et al., 2010 http://csg.sph.umich.edu/abecasis/public/
lipids2010/HDL2010.zip
Low density lipoprotein GWAS summary data Teslovich et al., 2010 http://csg.sph.umich.edu/abecasis/public/
lipids2010/LDL2010.zip
Total Cholesterol GWAS summary data Teslovich et al., 2010 http://csg.sph.umich.edu/abecasis/public/
lipids2010/TC2010.zip
Glucose sensitivity BMI adjusted GWAS
summary data
Manning et al., 2012 ftp://ftp.sanger.ac.uk/pub/magic/MAGIC_Manning_
et_al_FastingGlucose_MainEffect.txt.gz
Glucose sensitivity GWAS summary data Manning et al., 2012 ftp://ftp.sanger.ac.uk/pub/magic/MAGIC_
Manning_et_al_FastingGlucose_MainEffect.txt.gz
Insulin sensitivity BMI adjusted GWAS
summary data
Manning et al., 2012 ftp://ftp.sanger.ac.uk/pub/magic/MAGIC_Manning_
et_al_FastingGlucose_MainEffect.txt.gz
Insulin sensitivity GWAS summary data Manning et al., 2012 ftp://ftp.sanger.ac.uk/pub/magic/MAGIC_Manning_
et_al_FastingGlucose_MainEffect.txt.gz
Femoral neck bone mineral density GWAS
summary data
Estrada et al., 2012 http://www.gefos.org/sites/default/files/
GEFOS2_FNBMD_POOLED_GC.txt.gz
(Continued on next page)
e2 Cell 167, 1369–1384.e1–e10, November 17, 2016
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Lumbar spine bone mineral density GWAS
summary data
Estrada et al., 2012 http://www.gefos.org/sites/default/files/
GEFOS2_LSBMD_POOLED_GC.txt.gz
Diastolic blood pressure GWAS
summary data
Ehret et al., 2011 http://www.georgehretlab.org/ICBP-summary-
Nature.csv.gz
Systolic blood pressure GWAS
summary data
Ehret et al., 2011 http://www.georgehretlab.org/ICBP-summary-
Nature.csv.gz
Body Mass Index GWAS summary data Locke et al., 2015 https://www.broadinstitute.org/collaboration/
giant/images/1/15/SNP_gwas_mc_merge_
nogc.tbl.uniq.gz
Software and Algorithms
HiCUP Wingett et al., 2015 http://www.bioinformatics.babraham.ac.uk/
projects/hicup
HOMER Heinz et al., 2010 http://homer.salk.edu/homer/
CHiCAGO: calling interactions and computing
feature enrichment at PIRs
Cairns et al., 2016 http://regulatorygenomicsgroup.org/chicago
Sdef method Blangiardo et al., 2010 https://cran.r-project.org/web/packages/sdef
Autoclass Bayesian clustering Cheeseman et al., 1988 https://ti.arc.nasa.gov/tech/rse/synthesis-projects-
applications/autoclass/autoclass-c/
Specificity score computation This paper https://github.com/Steven-M-Hill/PCHiC-
specificity-score-analysis
chromHMM Ernst and Kellis, 2012 http://compbio.mit.edu/ChromHMM/
DESeq2 Love et al., 2014 https://www.bioconductor.org/packages/DESeq2
Ensembl Regulatory Build process Zerbino et al., 2015 http://www.ensembl.org/info/genome/funcgen/
regulatory_build.html
MMSEQ Turro et al., 2011 https://github.com/eturro/mmseq
LIMIX Lippert et al.,2014 https://github.com/PMBio/limix
Poor man’s imputation This paper https://github.com/ollyburren/CHIGP
Blockshifter This paper https://github.com/ollyburren/CHIGP
COGS algorithm This paper https://github.com/ollyburren/CHIGP
Wakefield’s synthesis of approximate
Bayes factors
Wakefield, 2009 https://github.com/ollyburren/CHIGP
GeneMania 3.4.0 plugin Montojo et al., 2010 http://genemania.org/plugin
Cytoscape 3.3.0 Cline et al., 2007 http://www.cytoscape.org
bioMaRt Durinck et al., 2009 https://www.bioconductor.org/packages/
biomaRt
ReactomePA Yu and He, 2016 https://www.bioconductor.org/packages/
ReactomePA
ClusterProfiler Yu et al., 2012 https://www.bioconductor.org/packages/
clusterProfiler
VEP McLaren et al., 2010 https://github.com/Ensembl/
ensembl-toolsCONTACT FOR REAGENT AND RESOURCE SHARING
As Lead Contact, Mikhail Spivakov is responsible for all reagent and resource requests. Please contact Mikhail Spivakov at mikhail.
spivakov@babraham.ac.uk with requests and inquiries. Raw data are shared under managed access in accordance with the ethical
consent signed by the volunteers. Recall of Cambridge BioResource volunteers is by application. Processed data have been made
publicly available as described below.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human primary blood cells were obtained from either a single healthy donor (Mon, Neu, M40 (2/3 reps), M41, M42 (1/3 reps), Ery,
EndP, nCD4 (1/4 reps), tCD4, tCD8 (2/3 reps), tB, FetT) or pooled from multiple healthy donors (MK, M40 (1/3 reps), M42 (2/3 reps),Cell 167, 1369–1384.e1–e10, November 17, 2016 e3
nCD4 (3/4 reps), naCD4, aCD4, nCD8, tCD8 (1/3 reps), nB). The samples were obtained after written informed consent under study
titles ‘‘A Blueprint of Blood Cells,’’ REC reference 12/EE/0040, and ‘‘Genes and mechanisms in type 1 diabetes in the Cambridge
BioResource,’’ REC reference 05/Q0106/20; NRES Committee East of England – Cambridgeshire and Hertfordshire.
METHOD DETAILS
Cell Isolation and Purity Test
Cells were isolated from venous or cord blood and in vitro cultured and differentiated in some cases following standard BLUEPRINT
protocols as detailed below and confirming purity by flow cytometry or morphological examination.
Monocytes were isolated from venous blood after CD16+ depletion and CD14+ selection of peripheral blood mononuclear
cells (PBMCs) by Miltenyi Biotec kits, as described in detail at http://www.blueprint-epigenome.eu/UserFiles/file/Protocols/
UCAM_BluePrint_Monocyte.pdf. Neutrophils were isolated from venous blood after erythrocyte lysis and CD16+ selection by Milte-
nyi Biotec kits. Macrophages were in vitro differentiated from monocytes isolated from venous blood. Briefly, M0 resting macro-
phages were obtained after stimulation with 50ng/ml M-CSF for 7 days of monocytes. M1 inflammatory macrophages were obtained
after stimulation of monocytes with 50ng/ml M-CSF for 6 days followed by LPS alone at 100ng/ml for the last 18 hours. M2 anti-in-
flammatory macrophages were obtained after stimulation of monocytes with of 15ng/ml IL-13 and 0.1uM Rosiglitazone. See http://
www.blueprint-epigenome.eu/UserFiles/file/Protocols/UCAM_BluePrint_Macrophage.pdf for full details.
Erythroblasts and megakaryocytes were cultured from CD34+ cells isolated from cord blood mononuclear cells obtained with the
human CD34 isolation kit (Miltenyi Biotec) as described in (Chen et al., 2014). Erythroblasts were cultured with erythropoietin, SCF
and IL3 for 14 days, while megakaryocytes were obtained by culturing CD34+ cells with thrombopoietin and IL1b in 10 days.
Endothelial precursors (blood outgrowth endothelial cells (BOECs)) were generated from circulating endothelial progenitors in
adult peripheral blood after long-term culturing of PBMCs with endothelial cell growth medium and colony isolation (Ormiston
et al., 2015).
Naive CD4+ lymphocytes were obtained from PBMCs from venous blood by using custom kit (Catalog#19309) from STEMCELL
Technologies. Total CD4+ lymphocytes were obtained from PBMCs from venous blood by negative selection using EasySep Human
CD4+ T Cell Enrichment kit (Catalog#19052) from STEMCELL Technologies.
Activated and non-activated total CD4+ T cells were enriched from whole blood using RosetteSep human CD4+ T cell enrichment
cocktail according to the manufacturer’s protocol (STEMCELL Technologies, Vancouver, Canada). The enriched CD4+ T cell culture
was washed twice in X-VIVO-15 media (Lonza, Basel, Switzerland) supplemented with 1% human AB serum (Lonza) and penicillin/
streptomycin (GIBCO, ThermoFisher). 250,000 CD4+ T cells (93–99% pure) were stimulated with anti-CD3/CD28 T cell activator
beads (Dynal, ThermoFisher). Beads were added at a ratio of 0.3 beads / 1 CD4+ T cell (75,000 beads / well) and the cells ± beads
were cultured for 4 hr at 37C + 5% CO2.
Naive CD8+ lymphocytes were obtained from PBMCs from venous blood by negative selection using EasySep Human Naive CD8+
T Cell Enrichment kit (Catalog#19158) from STEMCELL Technologies. Total CD8+ lymphocytes were obtained from PBMCs from
venous blood by negative selection using EasySep Human CD8+ T cell Enrichment kit (Catalog#19053) from STEMCELL Techno-
logies. Naive B lymphocytes were obtained from PBMCs from venous blood by negative selection using EasySep Naive B Cell
Enrichment kit (Catalog#19254) from STEMCELL Technologies. Total B lymphocytes were obtained from PBMCs from venous blood
by negative selection using EasySep Human B cell Enrichment kit (Catalog#19054) from STEMCELL Technologies. Foetal thymus
cells were obtained after cell disaggregation from fetal thymus tissue that was sourced from Advanced Bioscience Resources
(Alameda, CA, USA), processed and banked in accordance with UK Human Tissue Act 2004. Ficoll isolation was used to select
healthy cells.
Cell Fixation
8x107 cells per library were resuspended in 30.625 ml of DMEM supplemented with 10% FBS, and 4.375 ml of formaldehyde was
added (16% stock solution; 2% final concentration). The fixation reaction continued for 10 min at room temperature with mixing and
was then quenched by the addition of 5 ml of 1 M glycine (125mM final concentration). Cells were incubated at room temperature for
5 min and then on ice for 15 min. Cells were pelleted by centrifugation at 400g for 10 min at 4C, and the supernatant was discarded.
The pellet was washed briefly in cold PBS, and samples were centrifuged again to pellet the cells. The supernatant was removed, and
the cell pellets were flash frozen in liquid nitrogen and stored at 80C.
Hi-C Library Preparation
Hi-C library generation was carried with in-nucleus ligation as described previously (Nagano et al., 2015). Chromatin was then de-
crosslinked and purified by phenol-chloroform extraction. DNA concentration was measured using Quant-iT PicoGreen (Life Tech-
nologies), and 40 mg of DNA was sheared to an average size of 400 bp, using the manufacturer’s instructions (Covaris). The sheared
DNAwas end-repaired, adenine-tailed and double size-selected using AMPure XP beads to isolate DNA ranging from 250 to 550 bp.
Ligation fragments marked by biotin were immobilized using MyOne Streptavidin C1 DynaBeads (Invitrogen) and ligated to
paired-end adaptors (Illumina). The immobilized Hi-C libraries were amplified using PE PCR 1.0 and PE PCR 2.0 primers (Illumina)
with 7–8 PCR amplification cycles.e4 Cell 167, 1369–1384.e1–e10, November 17, 2016
Biotinylated RNA Bait Library Design
Biotinylated 120-mer RNA baits were designed to the ends of HindIII restriction fragments that overlap Ensembl-annotated pro-
moters of protein-coding, noncoding, antisense, snRNA, miRNA and snoRNA transcripts (Mifsud et al., 2015). A target sequence
was accepted if its GC content ranged between 25% and 65%, the sequence contained no more than two consecutive Ns and
was within 330 bp of the HindIII restriction fragment terminus. A total of 22,076 HindIII fragments were captured, containing a total
of 31,253 annotated promoters for 18,202 protein-coding and 10,929 non-protein genes according to Ensembl v.75 (http://grch37.
ensembl.org).
PCHi-C
Capture Hi-C of promoters was carried out with SureSelect target enrichment, using the custom-designed biotinylated RNA bait
library and custom paired-end blockers according to the manufacturer’s instructions (Agilent Technologies). After library enrich-
ment, a post-capture PCR amplification step was carried out using PE PCR 1.0 and PE PCR 2.0 primers with 4 PCR amplification
cycles.
Sequencing
Hi-C and PCHi-C libraries were sequenced on the Illumina HiSeq2500 platform. 3 sequencing lanes per PCHi-C library and 1
sequencing lane per Hi-C library were used.
QUANTIFICATION AND STATISTICAL ANALYSIS
Hi-C and PCHi-C Sequence Alignment
Raw sequencing reads were processed using the HiCUP pipeline (Wingett et al., 2015), which maps the positions of di-tags against
the human genome (GRCh37), filters out experimental artifacts, such as circularized reads and re-ligations, and removes all duplicate
reads. Library statistics are presented in Table S1.
Hi-C Data Processing and the Definition of TAD Boundaries
Aligned Hi-C data were analyzed using HOMER (Heinz et al., 2010). Using binned Hi-C data, we computed the coverage- and dis-
tance-related background in the Hi-C data at 25kb, 100kb and 1Mb resolutions, based on an iterative correction algorithm (Imakaev
et al., 2012). General genome organization in the eight selected cell types was compared by plotting the distance-and-coverage cor-
rected Hi-C matrices at 1Mb resolution, and by computing the compartment signal related (1st or 2nd) principle component of the
distance-and-coverage corrected interaction profile correlation matrix (Lieberman-Aiden et al., 2009) at 100kb resolution, with pos-
itive values aligned with H3K4me3 CHIP-seq in human CD20+ cells (https://www.encodeproject.org/experiments/ENCSR000DQR/
ENCFF001WXC). The compartment signal for the selected cell types in each replicate was plotted for comparison, and the genome-
wide concatenated ChIP-seq aligned principal components were clustered using hierarchical clustering (using 1 - Pearson correla-
tion as the distance metric). Directionality indices (Dixon et al., 2012) were calculated from the number of interactions 1Mb upstream
and downstream using a 25kb sliding window every 5kb steps, and were smoothed using a ± 25kb window. Topological domain
boundaries (TAD) were called between consecutive negative and positive local extrema of the smoothed directionality indices
with a standard score above 0.5. For each analyzed cell type, TADs called on individual biological replicates were merged by taking
the mean of the TAD boundary genome locations; TADs showing an overlap of less than 75% between biological replicates were
removed from the analysis.
PCHi-C Interaction Calling
Interaction confidence scores were computed using the CHiCAGO pipeline (Cairns et al., 2016). Briefly, CHiCAGO calls interactions
based on a convolution background model reflecting both ‘Brownian’ (real, but expected interactions) and ‘technical’ (assay and
sequencing artifacts) components. The resulting p values are adjusted using a weighted false discovery control procedure that spe-
cifically accommodates the fact that increasingly larger numbers of tests are performed at regions where progressively smaller
numbers of interactions are expected. The weights were learned based on the decrease of the reproducibility of interaction calls
between the individual replicates of macrophage samples with distance. Interaction scores were then computed for each fragment
pair as –log-transformed, soft-thresholded, weighted p values. Interactions with a CHiCAGO scoreR 5 in at least one cell type were
considered as high-confidence interactions.
Reciprocal Capture CHi-C
A capture system containing 949 PIRs identified in the PCHi-C experiments in at least one of the following cell types: activated, non-
activated CD4+ T cells, erythroblasts, and monocytes was used to probe the Hi-C material in these cell types. Data processing and
interaction detection were performed in the same way as for PCHi-C.Cell 167, 1369–1384.e1–e10, November 17, 2016 e5
Comparing PCHi-C and Reciprocal Capture Hi-C
Determining consistent signals between genomics datasets is a non-trivial problem that requires leveraging both false-positive and
false-negative rates (Blangiardo and Richardson, 2007; Jeffries et al., 2009), particularly in undersampled datasets such as PCHi-C
(Cairns et al., 2016). Here we took advantage of the sdefmethod (Blangiardo et al., 2010) to determine the so-called q2 thresholds on
CHiCAGO interaction scores that minimize the global misclassification error by balancing sensitivity and specificity. The q2 thresh-
olds (Ery: 0.27; MK: 0.14; nCD4: 1.23; aCD4: 1.20) were below 5 in all cases, indicating that the consistency range between PCHi-C
and reciprocal capture Hi-C datasets extends considerably below the high-confidence threshold used throughout the study (as also
evident from Figure S2A). The proportion of high-confidence interactions called in PCHi-C (CHiCAGO score > = 5) that fell within con-
sistency range in the reciprocal capture (score > = q2 in both experiments) were, respectively 96.3% (Ery), 98.7% (MK), 92.9%
(nCD4), and 91.6% (aCD4).
Promoter Interaction Localization with Respect to TADs
High-confidence PCHi-C interactions (CHiCAGO score > = 5) were classified as either ‘‘within-TAD’’ or ‘‘TAD boundary-crossing’’
(only interactions with baits located within TAD boundaries were considered in the analysis). Localization expected at random
was estimated by randomly reshuffling the distances between baits and the TAD boundaries on both their flanks across baits,
thus preserving the overall structure of promoter interactions and bait positioning within TADs.
Interaction Clustering and Principal Component Analysis
Interactions with a CHiCAGO score R 5 in at least one cell type were clustered by the Bayesian algorithm ‘‘autoclass’’ (Cheese-
man et al., 1988) based on the full range of asinh-transformed CHiCAGO scores in each cell type. The algorithm was trained on a
sample of 30,000 interactions, and then used in the ‘‘predict’’ mode to classify the complete dataset. The relative error parameter
was set to 0.1. This resulted in 34 clusters, with cluster sizes ranging from 108,066 interactions to 12 interactions and a mean
cluster size of 21,436 interactions. Clustering of the cell types based on their interaction profiles was performed using a hierarchi-
cal algorithm with average linkage, based on Euclidian distances. Principal component analysis was performed using the prcomp
function in R.
Definition of Specificity Scores
Consider a set of cell types I. Let xi denote themeasured value of a quantitative property (such as CHiCAGO interaction score or gene
expression level) for cell type i∈ I. Then, the specificity score sc for a given cell type c∈ I is a weighted mean of the differences xc – xi
for is c,
sc =
1P
isc
dc;i
X
isc
dc;iðxc  xiÞwhere the weights dc,i are distances between cell type c and cell types i, calculated using the complete dataset (e.g., CHiCAGO
interaction scores for all interactions or expression values for all genes; distances calculated using Euclidean distance
metric). The distance weights are introduced to account for imbalances in the distances between cell types. For example,
among the cell types considered here are three types of macrophages that are likely to have very similar profiles of the
measured property compared with other analyzed cell types (and so the distances between macrophage samples will also
be smaller than between macrophages and other cell types). The distance weights focus the calculation of sc on cell types
that are relatively more distant from cell type c. In this example therefore, they will result in the calculation of sc for each
type of macrophage placing relatively little weight on the other types of macrophages. Without this weighting, specificity scores
for macrophages would be smaller on average simply because macrophages are over-represented among the cell types
considered.
Calculation of Cluster Specificity Scores
For a given Autoclass cluster (Figure 2B), a specificity score sc was calculated for each cell type c using the equation above, with xi
defined as the mean asinh-transformed CHiCAGO score for cell type i (mean calculated across all interactions in the given cluster).
The distance weights weights dc,i were calculated based on the full set of CHiCAGO interaction scores. These cluster specificity
scores are shown in Figure 2C.
ATAC-Seq Data Analysis
Processed count data were downloaded from GEO (accession GSE74912). Samples were normalized using DESeq2 (Love et al.,
2014) and the mean normalized counts across replicates were computed for each sample. Regions attracting top 10% mean
normalized counts for each cell type were considered for PIR enrichment analysis. Enrichment at PIRs was computed using the
peakEnrichment4Features function in the CHiCAGO package (Cairns et al., 2016) with respect to randomized PIRs generated so
as to preserve the distribution of PIR distances to promoters.e6 Cell 167, 1369–1384.e1–e10, November 17, 2016
Histone Modification ChIP and the Definition of Chromatin States
Processed histone modification ChIP-seq datasets were downloaded from the BLUEPRINT project (the January 2015 GRCh37-
based release, ftp://ftp.ebi.ac.uk/pub/databases/blueprint/data/homo_sapiens/GRCh37/). Histone modification enrichment at
PIRs was computed using the peakEnrichment4Features function in the CHiCAGO package (Cairns et al., 2016) with respect to
randomized PIRs generated so as to preserve the distribution of PIR distances to promoters. To form genome segmentations,
ChromHMM (Ernst and Kellis, 2012) was applied to all BLUEPRINT samples with full reference epigenome histonemodification align-
ment files, using default settings and defining 25 epigenetic states. This dataset was used as the basis for the Ensembl Regulatory
Build process (Zerbino et al., 2015), defining regulatory features based on the histone profiles (transcription start site, proximal
enhancer, distal enhancer), and also assigning activity statuses based on sample-specific experiments (active, poised, repressed,
inactive) (Zerbino et al., 2016). Baits and PIRs were then overlapped with Ensembl Regulatory Build regulatory features.
Dynamics of Enhancer-Promoter Interactions
Hierarchical clustering was conducted on the presence or absence of high-confidence interactions (CHiCAGO score > = 5) and distal
enhancer activity defined as presented above, using binary distance and complete linkage. Enrichment was calculated as observed
over expected, where observed is the number of active distal enhancers overlapping PIRs, and expected is the expected number
under the null model of no association between enhancer activity and the presence of an interaction.
For the analyses in Figures 3Eand3F, one representativeBLUEPRINT samplewas selected for eachcell type toavoiddouble count-
ing interactions. A bait fragment was labeled ‘‘active’’ if it overlapped at least one promoter regulatory element in the chromHMM-
defined active state, and a PIR was labeled as ‘‘active’’ if it overlapped at least one distal enhancer in the chromHMM-defined active
state. Promoters and PIRs in all other states, including poised, repressed and inactive were considered as ‘‘non-active.’’ Removing
enhancers in the chromHMM-defined inactive state from the analysis in Figure 3F and considering only poised and repressed en-
hancers as non-active led to the same conclusions (overdispersion-adjusted p value = 0.0016; data not shown).
Sets were formed of overlapping promoter features and baits, and overlapping distal enhancers and PIRs. 2x2 contingency tables
were generated by summarizing these sets: either the full set (Figure 3E) or the subset where at least one cell type has a high-con-
fidence interaction between an active promoter and an active distal enhancer (Figure 3F). The p values for the null hypotheses of
independence between interaction state and regulatory state were calculated by the c2 test. Overdispersion was expected in the
underlying null distribution due to correlated observations arising from the shared baits of multiple interactions. Block bootstrapping
was therefore performed to estimate overdispersion by resampling baited fragments with replacement, and the observed c2-statistic
was scaled by a factor of sqrt(2) divided by the square root of the variance of the 1000 bootstrap-resampled c2-statistics.
Relationship between Active Enhancers and Gene Expression
BLUEPRINT gene expression data were obtained from EGA (https://www.ebi.ac.uk/ega, EGA: EGAS00001000327) and processed
as previously described (Chen et al., 2014), with quantification performed using MMSEQ (Turro et al., 2011). The data were then
filtered so that the Regulatory Build promoter feature was within 500 bp upstream and 50 bp downstream of an annotated transcrip-
tion start site for the gene. Only geneswith active promoters in all BLUEPRINT samples were used in this analysis, to remove the large
effect of promoter status on gene expression. A linear model was fitted by robust regression using iterated reweighted least-squares,
where the gene expression was modeled by either the number of interacting active enhancers (Figure 4A), or the number of any
interacting PIRs and the fraction of interacting active enhancers (Figure S4A).
Calculation and Clustering of Gene Specificity Scores (Interactions with Active Enhancers)
We quantified the cell type-specificity of each gene’s interactions with active enhancers through calculation of gene specificity
scores. This analysis was restricted to the eight cell types for which BLUEPRINT expression and histone modification data were
available. The original set of high-confidence interactions was filtered to (i) only contain baits that mapped exclusively to a unique
protein-coding gene promoter and (ii) only contain interactions for which at least one of the eight cell types has both a CHiCAGO
scoreR 5 and an active enhancer. For this analysis, PIRs were considered as ‘‘active enhancers’’ if they contained proximal/distal
enhancer or transcription start site features (based on the Ensembl Regulatory Build) that were found to be in the active state based
on ChromHMM segmentations of the histone modification data in the corresponding cell type. This resulted in a set of 139,835 in-
teractions and 7,004 unique baits. To focus the analysis on active enhancers, for each interaction CHiCAGO scores were set to zero
for cell types where the enhancer had an inactive status. Finally, to avoid large CHiCAGO scores dominating the specificity analysis,
scores were asinh-transformed and values larger than a threshold of 4.3 (equivalent to a scorez36.8) were set to 4.3. We refer to
these scores as ‘‘processed CHiCAGO scores.’’
For each enhancer-promoter interaction, specificity scores sc for each cell type c were calculated as described above (see ‘‘Defi-
nition of specificity scores’’ and equation therein), with xi defined as the processed CHiCAGO score for cell type i. The distance
weights weights dc,i were calculated based on the full set of CHiCAGO interaction scores (asinh-transformed with upper threshold
of 4.3). Now consider a single gene (protein-coding gene promoter) g. Let ng denote the number of enhancer interactions this gene
has among the set of 139,835 interactions. The gene then has ng specificity scores sc for cell type c, one for each interaction. These ng
scores are averaged to obtain the interaction-based gene specificity score for cell type c, sgc. The heatmap in Figure 4B shows these
scores for eight cell types and 7,004 genes.Cell 167, 1369–1384.e1–e10, November 17, 2016 e7
Clustering of genes based on these specificity scores was performed in R using k-means with Euclidean distance metric and
10,000 random starts each with a maximum of 10,000 iterations. The analysis was repeated with the number of clusters varying be-
tween 2 and 30. We selected 12 clusters (shown in Figure 4B) by inspecting the scree plot of within-cluster sum of squares versus
number of clusters. The cell types were also clustered according to their interaction-based gene specificity scores across genes.
Hierarchical clustering was applied with Euclidean distance and complete linkage (see dendrogram in Figure 4B).
Calculation of Gene Specificity Scores (Expression)
For each of the 7,004 genes, expression-based specificity scores sc were calculated for each cell type c based on BLUEPRINT
expression data, processed as previously described (Chen et al., 2014). The scores for each gene were calculated as described
above (see ‘‘Definition of specificity scores’’ and equation therein) with xi defined as the asinh-transformed gene expression value
for cell type i. The distance weights dc,i were calculated based on the full expression dataset.
Calculation of Gene Cluster Enrichment Scores
Scores were calculated to quantify enrichment of each of the 12 gene clusters in Figure 4B (capturing cell type-specificity of inter-
actions with active enhancers) for the 100 genes expressed with highest specificity in each analyzed cell type.
LetGc denote the set of 100 genes with highest expression-based gene specificity score for cell type c (Figures 4D and S4C show
interaction-based gene specificity scores for genes in Gc where c is nCD4 and monocytes respectively). Let pc,k denote the propor-
tion of genes inGc that are in cluster k and qk denote the proportion of all 7,004 analyzed genes that are in cluster k. Then, the cluster k
enrichment score for genes inGc is given by ec,k = pc,k - qk. Note that qk is the expected value of pc,kwhenGc is replaced by a random
selection of 100 genes.
Enrichment scores are shown in Figure 4E. Overall, gene clusters characterized by interactions that are predominantly specific to
cell type c were the most enriched for the 100 genes in Gc.
eQTL Analysis
To evaluate the number of lead eQTLs in monocytes and B cells (Fairfax et al., 2012) that physically contact their target gene pro-
moters, we performed association tests using LIMIX (Lippert et al., 2014) within 2Mb windows around the gene bodies. For each
gene expression probe, at most one lead eQTL SNP was considered at FDR < 10%. We then counted cases, whereby the lead
eQTL or at least one SNP in LD with it (r2 > = 0.8, based on the 1000 Genomes EUR cohort (Auton et al., 2015)) overlapped a PIR
for the eQTL-associated gene. The same strategy was taken to evaluate the number of PIRs detected in at least one of the 17
cell types overlapping cis-eQTLs (FDR < 10%) for the PIR target genes reported in the whole-blood meta-analysis study (Westra
et al., 2013).
To compute the enrichment of eQTLs at PIRs in the monocyte and B cell data (Fairfax et al., 2012), we used LIMIX to perform as-
sociation tests between each SNP overlapping each PIR and the expression of the respective PIR-connected gene probe. The same
analysis was performed at random regions (‘‘randomised PIRs’’) generated in a manner maintaining the distribution of distances and
spatial interdependencies of the observed PIRs and accounting for the strand directionality of the genes. Specifically, the bait posi-
tion of all PIRs of a given gene was shifted to the bait position of another randomly selected gene. This procedure was performed for
all genes over 1000 permutations. If the randomly selected gene was on the opposite strand compared to the gene of origin, the set
of interactions wasmirrored around the bait position. Enrichment was assessed by comparing a) proportions of SNPs that are eQTLs
for the PIR-connected target gene (Figures 5A and 5B) and b) proportions of PIR-connected genes with at least one significant
association (Figures S5A and S5B) at the observed and randomized PIRs over binned distances between the PIRs and the target
gene TSS. The p values were adjusted for all tests across variants and genes in each distance bin.
For the examples of SNPs in PIRs, associations of PIRs (plus extra 500bp on either side of them) with the connected gene expres-
sion were tested for each gene, and the p values were corrected globally for all tests across all variants and genes. Significant
associations were reported at FDR < 10%.
To assess the enrichment of whole-blood cis-eQTLs at the PIRs of their target genes (Figure S5C), we randomized PIRs in the same
way as for the monocyte and B cell analysis presented above, and compared the overlap of observed versus randomized PIRs with
the lead eQTL SNPs for the PIR-connected genes or SNPs in LD with them.
GWAS Summary Statistics
Blood trait summary data (Gieger et al., 2011; van der Harst et al., 2012) were kindly provided by N. Soranzo and the HaemGen con-
sortium; autoimmune disease summary data were retrieved from ImmunoBase (http://www.immunobase.org) (Anderson et al., 2011;
Barrett et al., 2009; Bentham et al., 2015; Cordell et al., 2015; Dubois et al., 2010; Franke et al., 2010; Sawcer et al., 2011; Stahl et al.,
2010); the remaining GWAS summary data were retrieved from various internet resources (Estrada et al., 2012; Ehret et al., 2011;
Locke et al., 2015; Manning et al., 2012; Morris et al., 2012; Teslovich et al., 2010; Wood et al., 2014). Where necessary we used
liftOver or in-house scripts to convert to GRCh37 coordinates. In order to remove SNPs with spuriously strong association statistics,
we removed SNPs with p < 5 3 108 for which there were no SNPs in LD (r2 > 0.6 using 1000 genomes EUR cohort as a reference
genotype panel (Auton et al., 2015)) or within 50 Kb with p < 105.e8 Cell 167, 1369–1384.e1–e10, November 17, 2016
Poor man’s Imputation (PMI)
We developed a pipeline that approximates the p value for missing SNP summary statistics for a given study using a suitable refer-
ence genotype set. First we split the genome into regions based on a recombination frequency of 0.1cM using HapMap recombina-
tion rate data (Frazer et al., 2007). For each region we retrieve from the reference genotype set (1000 genomes EUR cohort (Auton
et al., 2015)) all SNPs that haveMAF > 1% and use these to compute pairwise LD.We pair each SNP from our summary statistics set,
where p values are present, with SNPs from the reference set where p values are unavailable using maximum pairwise r2 (r2Max). If
r2Max > 0.6, we then impute the missing p value as that at the paired SNP. SNPs with missing data without a pair above this r
2
Max
threshold are discarded as are SNPs that are included in the study but don’t map to the reference genotype set. We masked
the MHC region (GRCh37:6:25-35Mb) from all downstream analysis due to its extended LD and known strong and complex
association with autoimmune diseases.
GWAS Tissue Set Enrichment Analysis of PCHi-C
Wedeveloped amethod, blockshifter, based on ideas implemented in GOSHIFTER (Trynka et al., 2015) to examine the enrichment of
GWAS signals at PIRs in order to overcome linkage disequilibrium (LD) and interaction fragment correlation. Blockshifter implements
a competitive test of enrichment between a test set of PIRs compared to a control set. First the coordinates of the PIR in the union of
test and control sets are retrieved, and PIRs with no GWAS signal overlap, or that are found in both test or control set are discarded.
For the remaining PIRs we store the number and sum of overlapping GWAS posterior probabilities and these are used to compute d,
the difference in the means between the test and control sets. Due to spatial correlation between GWAS signals and between PIRs
the variance of d is inflated, we therefore compute it empirically using permutation. Runs of one or more PIRs (separated by at most
one HindIII fragment) are combined into ‘blocks’, that are labeled unmixed (either test or control PIRs) or mixed (block contains both
test and control PIRs). Unmixed blocks are permuted in a standard fashion by reassigning either test or control labels randomly, tak-
ing into account the number of blocks in the observed sets. Mixed blocks are permuted by conceptually circularising each block and
rotating the labels (Figure S6A). We then randomly sample from each these precomputed block permutations n times so that the pro-
portion of underlying PIR labels is the same as the observed set, and use this to compute the set of dnull. We use dnull to compute an
empirical Z-score:
Z =
d dnullffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
VarðdnullÞ
p
Integration of GWAS Summary Statistics with Tissue Specific PCHi-C and Functional Information
In order to prioritize genes, traits and tissues for further study we developed the COGS algorithm to compute tissue specific gene
scores for each GWAS trait, taking into account linkage disequilibrium, interactions and functional SNP annotation. For each
GWAS trait, and for each SNP in a given recombination block, we used Wakefield’s synthesis (Wakefield, 2009) to compute approx-
imate Bayes factors and thus the posterior probability for that SNP being causal for that trait assuming at most one causal variant in
the recombination block (Maller et al., 2012). For each gene annotation, for which we have at least one high-confidence interaction
(CHiCAGO score > = 5), and recombination block we compute a block gene score that is composed of the contributions of three
components: (1) coding SNPs in the annotated gene as computed by VEP (McLaren et al., 2010), (2) promoter SNPs, which we define
as SNPs that overlap a region encompassing the bait and flanking HindIII fragments and not any coding SNPs, (3) SNPs that overlap
PIRs for a tissue or set of tissues that do not overlap coding SNPs. Thus for a given target gene, recombination block and trait we can
derive a block ‘‘genescore’’ that is the sumof the posterior probabilities (as computed by PMI) of SNPs overlapping each component.
We assume statistical independence between blocks, so that we can combine block genescores to get an overall ‘‘genescore’’:
genescore= 1
Y
ð1 genescore:blockÞ:
TAD-Based Prioritization
To compare COGS with ‘‘brute-force’’ TAD-based prioritization, we computed TAD-level scores for eight autoimmune traits across
eight cell types. Briefly, for each TAD in each cell type, we subdivided and summed posterior probabilities for each trait (excluding the
MHC region) by overlap with 0.1cM recombination blocks to obtain block TAD scores, removing coding SNPs, and computed an
overall TAD score such that:
TAD:score= 1
Y
ð1 TADscore blockÞ:
A TAD score was assigned to each genemapping within the respective TAD in each tissue, and themaximum score across all eight
cell types was selected.
Prioritized Gene Enrichment in IBD Differentially Expressed Genes
Normalized microarray expression data for sorted CD4+ T cells, CD8+ T cells, B cells, Monocytes and Neutrophils in 49 patients with
Crohn’s disease (CD), 42 with ulcerative colitis (UC) and 43 healthy controls (Peters et al., 2016) was downloaded from ArrayExpressCell 167, 1369–1384.e1–e10, November 17, 2016 e9
(accession E-MTAB-3554). We then used limma (Ritchie et al., 2015) to perform a two-degree-of-freedom test for differential expres-
sion across any of the three patient groups, combining individual gene differential expression across cell types by selecting the most
significant cell type. Fisher’s test was used to compute enrichment across all protein coding genes that had both expression
and COGS scores for UC (Anderson et al., 2011) and CD (Franke et al., 2010). For comparison with TAD-based prioritized genes
in Figure S6C, COGS prioritization was rerun using only eight cell types for which Hi-C data (and therefore TAD information) was
available, with both MHC and coding variation masked.
Reactome Pathway Analysis
For each trait we selected all protein coding genes having an overall gene score above 0.5. We converted Ensembl gene identifiers
to Entrez identifiers with bioMaRt (Durinck et al., 2009) and then used ReactomePA (Yu and He, 2016) to compute enrichment of
genes in Reactome pathways using an FDR cutoff of 0.05. We generated a bubble plot of significant results for each trait using
ClusterProfiler (Yu et al., 2012).
Core Autoimmune Network
For each of the eight analyzed autoimmune traits (CD, CEL, RA, UC, PBC, SLE, MS, T1D) we selected top-scoring genes based on
the following criteria: genescore > 0.5, nomore than top 75 genes per condition. The resulting 421 genes were combined into a single
list, and disease associations were assigned to each gene based on the respective genescore > 0.5. This gene list was used as input
to the GeneMania 3.4.0 plugin (Montojo et al., 2010) for Cytoscape 3.3.0 (Cline et al., 2007) to construct a network based on prior
knowledge about these 421 genes (shown in Figure 6E). The following information was used for linking gene pairs: physical interac-
tion (all sources in the plugin), co-localization (the ‘‘Satoh-Yamamoto-2013’’ dataset only), predicted interaction (I2D-based datasets
only), shared pathway annotation. Only the 421 network genes were plotted (‘‘find 0 related genes’’) and query-gene-based weights
were used. The Cytoscape network file is available through Open Science Framework (https://osf.io/u8tzp).
DATA AND SOFTWARE AVAILABILITY
Software
Scripts to compute specificity scores are available at https://github.com/Steven-M-Hill/PCHiC-specificity-score-analysis. Imple-
mentations of the PMI, blockshifter and COGS algorithms, along with supporting documentation, are available at https://github.
com/ollyburren/CHIGP.
Data Resources
The accession number for the raw sequencing reads reported in this paper that were deposited to EGA (https://www.ebi.ac.uk/ega)
is EGAS00001001911. Lists of PHi-C-detected significant interactions, detected interactions between active promoters and active
enhancers, and a comparison of interactions scores between PCHi-C and reciprocal capture Hi-C experiments are available as part
of the Data S1 archive. High-confidence interactions (CHiCAGO score > = 5 in at least one cell type) are available via the CHiCP
browser (Schofield et al., 2016), where they can be visualized alongside GWAS data (https://www.chicp.org) and as custom tracks
for the Ensembl browser (ftp://ftp.ebi.ac.uk/pub/contrib/pchic/CHiCAGO). The regulatory build annotations and segmentations of
the BLUEPRINT datasets are available as a track hub for the Ensembl browser (ftp://ftp.ebi.ac.uk/pub/contrib/pchic/hub.txt). Further
processed datasets, including TAD definitions, regulatory region annotations, specificity scores and gene prioritization data, are
available via Open Science Framework (https://osf.io/u8tzp).e10 Cell 167, 1369–1384.e1–e10, November 17, 2016
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Figure S1. Higher-Order Topological Properties of Eight Blood Cell Types, Related to Figure 1
(A) Top panel: Distributions of the frequencies of promoter interactions (per bait) that cross the cognate TAD boundaries in three representative cell types. Black
bars show the observed frequencies, and gray bars show expected frequencies computed by permuting TAD boundaries 1000 times (see Quantification and
Statistical Analysis). The error bars show ± standard deviations of 1000 permutations. On the x axis, 1 corresponds to a scenario whereby all interactions of a
given bait localize within the same TAD as the bait, and 0 corresponds to a scenario whereby all interactions of a given bait cross TAD boundaries. Bottom panel:
examples of baits with PIRs mapping fully within (left) or fully outside (right) the baits’ TADs. Purple bars show baited regions, black arrows show the direction of
the corresponding genes’ transcription, purple arcs show high-confidence interactions called byCHiCAGO (score >= 5), orange bars show TADboundaries. Plots
above show the directionality index (DI) profiles in the displayed regions, with TAD boundaries defined on the basis of a switch from a negative to a positive DI.
(B) Coverage-and-distance corrected Hi-C matrices of chromosome 1 show the log2-enrichment of interactions between chromatin segments binned at 1Mb
resolution. The eight analyzed cell types (MK,megakaryocytes; Ery, erythroblasts; Neu, neutrophils; Mon,monocytes; M40,macrophagesM0; nCD4, naive CD4+
T cells; nCD8, naive CD8+ T cells; nB, naive B cells) are shown in columns, and the respective biological replicates are in rows.
(C) The first principal component of the 100kb-binned interaction correlation matrix for chromosome 1 shows compartmentalisation (positive values are
associated with A and negative values with B compartment). Each biological replicate of the eight analyzed cell types is shown.
(D) Correlation matrices of the genome-wide concatenated first principal components with dendrograms from hierarchical clustering show the grouping of cell
types according to the compartment signal.
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Figure S2. Validation of Promoter Interactions Using Reciprocal Capture Hi-C, Related to Figure 1
(A) Cumulative density plots showing the distributions of asinh-transformed CHiCAGO interaction scores for promoter-containing reciprocal capture Hi-C
fragment pairs that are detected as high-confidence interactions (HCI) in the PCHi-C analyses in the respective cell types (blue line - HCI; CHiCAGO score > = 5)
(legend continued on next page)
versus those that are not detected as HCI in PCHi-C (gray line). Vertical lines show the high-confidence CHiCAGO score cutoff of 5 on the asinh-transformed scale
(2.31) for the reciprocal capture Hi-C samples and the q2 cutoffs minimizing the total misclassification error across the PCHi-C and reciprocal capture Hi-C
samples for each cell type (Blangiardo and Richardson, 2007). See Quantification and Statistical Analysis.
(B and C) Comparison of interactions detected with PCHi-C (top) and reciprocal capture (bottom two panels) for two example regions in erythroblasts (Ery, panel
B) and non-activated CD4 cells (naCD4, panel C). The PCHi-C baits capture the TRPC3 and TES promoters, respectively, while reciprocal capture baits were
designed to capture their selected PIRs. Interactions are plotted in the same way as in Figure 1C.
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Figure S3. Additional Properties of Promoter Interactions, Related to Figures 2 and 3
(A) Venn diagram showing the numbers of promoter baits with interactionsmapping to the ‘‘myeloid’’, ‘‘lymphoid’’ and ‘‘invariant’’ sets of clusters. See Figures 2B
and 2C and the main text for details. Includes 141 non-promoter-containing baits that are not considered in further analyses.
(B) Evidence that promoters preferentially have interactions with a similar cell type specificity. A histogram of the observed variance of the specificity scores
across interactions of the same bait (blue) versus the same obtained by permuting cluster labels (expected, gray). The specificity score for a given interaction was
taken to be the maximum of the interaction’s cluster specificity scores across all cell types. See Quantification and Statistical Analysis.
(C) Significance of PIR enrichment for chromatin accessibility regions detected by ATAC-seq in five blood cell types (tB, total B cells; tCD4, total CD4+ T cells;
tCD8, total CD8+ T cells; Ery, erythroblasts; Mon, monocytes) (Corces et al., 2016) in comparison with distance-matched random regions, expressed in terms of
z-scores. Error bars show ± SD across 100 draws of random regions.
(D) A zoomed-out view of promoter interactions and chromatin features in and around the b-globin locus. PCHi-C data from 3 cell types (Ery, erythroblasts; Mon,
monocytes; nCD8, naive CD8+ T cells), showing regulatory element annotations from the Ensembl Regulatory Build, colored by feature, and chromatin activities
based on ChromHMM segmentations of BLUEPRINT histone modification data. (ChromHMM activities included four states: ‘‘active’’, ‘‘poised’’, ‘‘Polycomb-
repressed’’, and ‘‘inactive’’, with only ‘‘active’’ and ‘‘inactive’’ states observed in the region shown). The image is based on a screenshot produced with Ensembl
v83 using GRCh37 assembly and GENCODE v19 gene annotations. The b-globin Locus Control Region (LCR) is highlighted in a blue box.
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Figure S4. Additional Evidence of the Link between Promoter Interactions and Gene Expression, Related to Figure 4
(A) Partial residual plot of log2-gene expression as a function of the number of PIRs interacting with the respective baited region in the cell types, where the
promoter is active in all analyzed cell types. The trendline is from a linear regression using iterated reweighted least-squares (see Quantification and Statistical
Analysis).
(B) Mean gene specificity score (based on interactions with active enhancers) for each of the clusters in Figure 4B is plotted against analogous mean gene
specificity scores based on expression data for monocytes (Mon) and macrophages M0, M1, M2 (M40-2). Error bars indicate ± SD. Plots for nCD4, MK, Ery and
Neu are shown in Figure 4C. See Quantification and Statistical Analysis for details.
(C) A subset of the heatmap in Figure 4B, showing interaction-based gene specificity scores for the top 100monocyte-specifically expressed genes (obtained by
ranking genes according to their monocyte (Mon) expression-based specificity scores), together with cluster IDs.
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Figure S5. Further Details on the Enrichment of eQTLs at Promoter-Interacting Regions, Related to Figure 5
(A and B) The proportion of genes with at least one eQTL SNP per gene expression probe located within PIRs compared with the equivalent proportion of eQTL
SNPs located within matched random regions (‘‘randomised PIRs’’) in monocytes (A) and total B cells (B). See Quantification and Statistical Analysis for details on
the randomization strategy. Asterisks represent the significance of enrichment at observed versus randomized PIRs (permutation test *p < 0.05; **p < 0.01; ***p <
0.001).
(C) Number of lead cis-eQTLs in whole blood (FDR < 10%) physically contacting regulated gene promoters (accounting for linkage disequilibrium). Results
obtained with randomized PIRs are shown as controls. Asterisks represent the significance of enrichment at observed versus randomized PIRs (permutation test
*p < 0.05; **p < 0.01; ***p < 0.001).
(D) An example of an extremely long-range eQTL association between rs3817995 andAURKA expression in total B cells, with the SNP located > 30Mb away from
AURKA transcription start site (TSS). The gray dashed line represents the significance threshold.
(E) An example of two independent eQTL signals detected for NCOA4 in monocytes, with the primary eQTL SNP (rs4948673) located > 5 Mb away from the TSS.
The second, independent eQTL SNP (rs10821610) is located close (< 20kb) to the NCOA4 TSS. The gray dashed line represents the significance threshold.
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Figure S6. Colocalization of GWAS and eQTL Signals at Prioritized Candidate Genes, Related to Figure 6
(A) A schematic of the permutation strategy implemented in blockshifter. GWAS summary statistics are converted to posterior probabilities for a given SNP to be
causal (red dots depict SNPs likely to be causal, blue dots depict other SNPs). Blocks of adjacent PIRs found in either test (purple) or control (cyan) tissue sets,
separated by two or more non-PIR HindIII fragments (gray), are then defined. Labels of HindIII fragments within each block are then rotated (‘block-shifted’) to
generate test sets for estimating the empirical variance of the test statistic under the null while accounting for genomic structure.
(B) Comparison of COGS prioritization scores with those obtained using a ‘‘brute-force’’ algorithm based on shared TADs for eight autoimmune (AI) diseases (see
Quantification and Statistical Analysis for details). Quadrants correspond to genes not exceeding the score cutoff of 0.5 with both methods, and exceeding it with
just one or both methods. Counts of genes in each quadrant are shown.
(C) Odds ratios of differential expression in the immune cells of irritable bowel disease (IBD) patients (FDR < 5%) (Peters et al., 2016) for genes prioritized for
Crohn’s disease (purple) and ulcerative colitis (blue) by the PCHi-C-based COGS or a TAD-based algorithm (score > 0.5).
(D–G). 2 Mb windows around the genes prioritized by the GWAS/PCHi-C based algorithm in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
were overlappedwith eQTLs for the same genes in B cells. In five cases high LD (r2 > 0.8) was detected between theGWAS lead SNP and the eQTL lead SNP in the
2Mb regions. Shown are Manhattan plots for two SLE-prioritized genes (SLC15A4, panel D; BLK, panel E) and two RA-prioritized genes (GIN1, panel F;
RASGRP1, panel G), for which high LD (r2 > 0.8) was detected between the GWAS lead SNP and the eQTL lead SNP, providing evidence for colocalization of the
GWAS and eQTL signals in these regions.
